CAS 119386-96-8

Mofegiline

Description:

Mofegiline is a chemical compound primarily recognized for its role as a selective monoamine oxidase B (MAO-B) inhibitor, which is significant in the treatment of neurodegenerative disorders, particularly Parkinson's disease. It is characterized by its ability to enhance dopaminergic activity in the brain by preventing the breakdown of dopamine, thus potentially alleviating symptoms associated with dopamine deficiency. Mofegiline is typically administered in its hydrochloride salt form, which enhances its solubility and bioavailability. The compound exhibits a moderate to high affinity for MAO-B, making it effective in therapeutic applications. Its pharmacokinetic profile suggests that it has a relatively long half-life, allowing for once-daily dosing in clinical settings. Additionally, Mofegiline's safety and efficacy have been evaluated in various studies, although it may present side effects typical of MAO inhibitors, such as dietary restrictions to avoid hypertensive crises. Overall, Mofegiline represents a valuable option in the pharmacological management of Parkinson's disease, contributing to improved quality of life for patients.

Formula: C₁₁H₁₃F₂N

InChI: InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+

InChI key: InChIKey=VXLBSYHAEKDUSU-JXMROGBWSA-N

SMILES: C(C/C(=C\F)/CN)C1=CC=C(F)C=C1

Synonyms:

• (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
• (2Z)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
• (E)-2-(4-Fluorophenethyl)-3-fluoroallylamine
• (E)-2-(Fluoromethylene)-4-(4-fluorophenyl)butylamine
• (E)-2-(Fluoromethylene)-4-(p-fluorophenyl)butylamine
• (E)-4-Fluoro-b-(fluoromethylene)benzenebutanamine
• (βE)-4-Fluoro-β-(fluoromethylene)benzenebutanamine
• Benzenebutanamine, 4-fluoro-β-(fluoromethylene)-, (E)-
• Benzenebutanamine, 4-fluoro-β-(fluoromethylene)-, (βE)-
• Btt 2089
• Mdl 72974